• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    1.239 -0.071 (-5.39%)
    Streaming Delayed Price Updated: 3:14 PM EDT, Apr 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Clearmind Medicine Inc. - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Top movers analysis one hour before the close of the markets on 2025-12-11: top gainers and losers in today's session. ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    Top stock movements in today's session. ↗
    Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
    Via Chartmill
    News headline image
    Clearmind Medicine Announces 1-for-40 Reverse Share Split
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are gapping on Wednesday? ↗
    The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
    Via Chartmill
    News headline image
    Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
    Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
    Via Chartmill
    News headline image
    Curious about the most active stocks on Tuesday? ↗
    Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! 
    Via Chartmill
    News headline image
    Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.